Health
Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations – GlobeNewswire
– Second Product Candidate Expected to Enter Clinic in First Half of 2021 – Preclinical Data Underscore Treatment Potential for PBFT02 in Frontotemporal…
Second Product Candidate Expected to Enter Clinic in First Half of 2021
Preclinical Data Underscore Treatment Potential for PBFT02 in Frontotemporal Dementia with Granulin (GRN) Mutations, a Devastating, Progressive Disorder Impacting Adults with No Approved Disease-Modifying Therapy Options
PHILADELPHIA, Jan. 28, 2021 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS)…
-
General14 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News23 hours agoRainbow Beach surfer’s untold 7/7 story
-
Noosa News13 hours agoWoman airlifted to Brisbane hospital after big cat mauling at south-east Queensland zoo near Toowoomba
-
Business20 hours agoInvested $10,000 in Westpac shares 2 years ago? Guess how much you’ve already banked!